

## Indegene Receives \$200 Million Investment from Carlyle and Brighton Park

### Torreya advised Indegene on the transaction

Bangalore, India and New Jersey, February 2, 2021

Indegene, an enterprise healthtech solutions provider based in Bangalore, India, announced that Carlyle and Brighton Park Capital will acquire minority stakes in the company for US\$200 million.

Indegene has emerged as a leading digital transformation partner to the global life sciences industry. With more than 3,000 employees across North America, Europe, China, Japan and India, Indegene provides technology platforms and commercialization services to pharmaceutical, biotechnology, and medical device companies. Clients partner with Indegene to design, build, and manage digital-first operations that leverage data and automation to accelerate clinical development, improve regulatory compliance, enhance customer experience, and drive commercial success.

With strong tailwinds driving increasing reliance on digital platforms within the industry, Indegene plans to use the primary investment from Carlyle and Brighton Park to accelerate its M&A and global expansion strategy.

Torreya advised Indegene on the transaction, which highlights Torreya's strength in advising companies in the pharmaceutical services sector and strong relationships within the private equity community. In the past 24 months, Torreya has raised over \$800 million in private capital for our clients.

### ABOUT INDEGENE:

For more information about Indegene, please see: [www.indegene.com](http://www.indegene.com)

### ABOUT THE CARLYLE GROUP:

For more information about Carlyle, please see: [www.carlyle.com](http://www.carlyle.com)

### ABOUT BRIGHTON PARK CAPITAL:

For more information about Brighton Park, please see: [www.brightonparkcap.com](http://www.brightonparkcap.com)

### Deal Press Release

#### Torreya Contact

**TOM BABICH**

Head of Capital Markets | New York Office

[tom.babich@torreya.com](mailto:tom.babich@torreya.com) | 212.257.5811 | [torreya.com](http://torreya.com)



Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.